3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
183
Cisplatin
159
Radiotherapy
77
Carboplatin
71
Radiotherapy, Intensity-Modulated
70
Cetuximab
68
Magnetic Resonance Spectroscopy
65
Nivolumab
64
Paclitaxel
52
Docetaxel
50
Specimen Handling
45
Radiation
34
Gemcitabine
33
Fluorouracil
31
Surveys and Questionnaires
28
Biopsy
27
toripalimab
26
Drug Therapy
26
Platinum
25
Surgical Procedures, Operative
24
Standard of Care
23
1,2-diaminocyclohexaneplatinum II citrate
23
cemiplimab
22
atezolizumab
20
Capecitabine
20
Ipilimumab
19
Chemoradiotherapy
19
tislelizumab
18
durvalumab
18
Taxes
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
ficlatuzumab
×
Head & Neck
×
1 year
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled